Mirex, a chlorinated hydrocarbon previously used as a systemic insecticide and flame retardant, is a nongenotoxic hepatocarcinogen in both rats and mice. In liver, mirex induced biochemical responses and hyperplasia characteristic of increased cell proliferation, which is consistent with its role as a liver tumor promoter. We have recently shown that mirex is a potent nonphorbol ester-type skin tumor promoter in 7, 12-dimethylbenz[a]anthracene (DMBA)-initiated mice. However, unlike its effect in liver, a single topical application of mirex to skin does not induce the acute biochemical responses, such as increased epidermal DNA synthesis and ornithine decarboxylase activity, indicative of increased cell proliferation. Multiple topical applications of mirex over a 1 month period induced only a minimal increase in the number of epidermal nucleated cell layers, which contrasts with definitive hyperplasia induced by a comparable tumor-promoting dose of 12-0-tetradecanoylphorbol-13-acetate (TPA). Collectively, these data indicated that mirex is promoting through a novel mechanism. Further evidence that mirex promotes tumors through a mechanism distinct from that of the prototypical skin tumor promoter, TPA, was obtained by examining the effect of their simultaneous co-treatment. The co-application of mirex and TPA yielded a tumor multiplicity greater than the sum of the responses of each promoter individually. In summary, our results demonstrate that mirex, a carcinogenic and hyperplastic agent in liver, is also a very effective tumor promoter in mouse skin, but suggest that mirex operates via a novel mechanism in skin that may involve only a minimal role for enhanced cell proliferation.
Introduction
Recent studies on human colon cancer have suggested that multiple, cumulative genetic lesions are required for carcinogenesis (1) . However, approximately onethird of the carcinogens detected in the National Toxicology Program rodent bioassay are nongenotoxic in short-term, in vitro tests (2) and thus may include tumor promoters as defined by experimental models of multistage chemical carcinogenesis. Tumor promoters are carcinogens that have classically been thought to act through nongenotoxic mechanisms to expand populations of cells previously damaged by exposure to a subcarcinogenic dose of a genotoxic initiating chemical (3) . Because previously identified tumor promoters cause varying degrees of increased cell proliferation, one explanation for their enhancement of carcinogenesis is that these compounds are indirectly genotoxic as a consequence of increasing the occurrence of errors normally made during DNA replication (4, 5) .
Mirex is a chlorinated hydrocarbon previously used as a systemic insecticide and as a flame retardant. Its use in the United States was banned by the Environmental Protection Agency, in part because it is hepatocarcinogenic in both rats and mice (6) (7) (8) (9) . Although it has not been formally tested in an initiation-promotion protocol for liver carcinogenesis, mirex is not genotoxic in short-term, in vitro tests (9, 10) and inhibits gap junctional communication (11) , two characteristics of tumor promoters. Mirex induces proliferation of hepatocyte smooth endoplasmic reticulum (12, 13) and mixed-function oxidase activities (14, 15) , as also occurs during the adaptive response of liver to other xenobiotic tumor promoters, such as phenobarbital (16) . Consistent with the above hypothesis relating tumor promotion and cell proliferation, mirex stimulates liver growth, in part through hyperplasia (17) which is preceded by induction of ornithine decarboxylase activity (17, 18) and stimulation of DNA synthesis (17, 19) .
We have recently reported that mirex is a nonphorbol ester-type skin tumor promoter in 7,12-dimethylbenz[a]anthracene (DMBA)-initiated female mice (20) . A maximally promoting dose of mirex (200 nmole, 3 times/week) resulted in a tumor incidence of 96% with a multiplicity of 16 
Results
We have shown that mirex is a potent skin tumor promoter in DMBA-initiated female CD-1 mice (20) . After 20 weeks of thrice weekly application, 50 nmole mirex yielded 60% incidence of tumor-bearing mice with an average multiplicity of 4 tumors/mouse, while 200 nmole mirex, maximal promoting dose, yielded 96% tumor incidence with a multiplicity of 16 tumors/ mouse. For comparison, thrice weekly application of 2 nmole TPA gave 78% tumor incidence with 15 tumors/ mouse. In contrast to the well-characterized biochemical responses to TPA, a single topical application of 200 nmole mirex did not induce epidermal ornithine decarboxylase activity or increase DNA synthesis, as assessed by [3H]thymidine pulse labeling. We have evaluated time courses from 5 to 56 hr for ornithine decarboxylase and from 18 to 108 hr for DNA synthesis to encompass peak response times found with other tumor promoters and have found no evidence of stimulation of these events by mirex (20) .
As shown in Figure 1 , we have morphologically examined skins treated repeatedly (3 times/week for 4 weeks) with comparable promoting doses of mirex (200 nmole) or TPA (2 nmole) for evidence of epidermal hyperplasia. Multiple applications of mirex for 1 month resulted in only a minimal increase in the number of nucleated epidermal cell layers, from one to two in acetone-treated epidermis (Fig. 1A) to two to three in mirex-treated epidermis (Fig 1C) . In contrast, a definitive hyperplastic response of six to seven nucleated epidermal cell layers was observed after repeated treatment with TPA; (Fig. 1B) 
Discussion
We describe here results extending our previous work (20) demonstrating that mirex is a potent tumor promoter in DMBA-initiated mouse skin and that mirex promotes skin tumors through a novel mechanism involving minimal cell proliferation. Previously we demonstrated the inability of mirex to induce acute biochemical responses indicative of increased cell proliferation, i.e., increased epidermal DNA synthesis and induction of ornithine decarboxylase activity, that are generally observed in response to single applications of other skin tumor promoters (20) . Consistent with these results, we have shown that multiple applications of mirex over 1 month did not induce significant epidermal hyperplasia, especially when contrasted with the response to a comparable tumor-promoting dose of TPA (Fig 1) . This observation is particularly supportive of a mechanism for mirex-induced tumor promotion that involves a relatively minor role for cell prolifera- tion, because sustained, chronic hyperplasia has been considered one of the best correlates of skin tumorpromoting activity (21) . Skin tumor promoters have been generally divided into two classes, the phorbol ester-type and nonphorbol ester-type, depending on whether they activate protein kinase C (PKC) enzymatic activity or compete with TPA binding to protein kinase C of in vitro preparations (22) (23) (24) . We 1 and 2A (26) , and for thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+-ATPase (27) . Further, nonphorbol ester-type and phorbol ester-type tumor promoters can synergize in the induction of common biological responses, such as stimulation of arachidonic acid metabolism in C-9 rat liver cells (28) and induction of gene expression from AP-1 sites in Rat-1 cells (29) . We have shown here that mirex can synergize the TPA in the promotion of skin tumors (Fig. 2) . This result lends further support to the hypothesis that mirex and TPA promote through different mechanisms and suggests that these distinct mechanisms can complement each other.
The extensive hyperplasia induced by TPA appears to be a generalized response, i.e., it appears that all basal cells of the epidermis are stimulated to proliferate. Our inability to detect mirex-induced biochemical and morphological responses associated with increased epidermal cell proliferation does not mean that cell proliferation is not increased during mirex-induced tumor promotion. It has been emphasized that the hypothesis relating tumor promotion to cell proliferation predicts that proliferation will be stimulated in initiated cells (5). Thus, we speculate that mirex selectively enhances proliferation of initiated epidermal cells without inducing a generalized hyperplastic response. We would thus not expect to see hyperplasia or increased DNA synthesis in uninitiated skin, which is classically used to evaluate these short-term responses. If this speculation is true, then mirex could be an important exception to the correlation that tumor-promoting activity is related to sustained epidermal hyperplasia (21) . As such, mirex may provide a unique and important tool for identification and study of early preneoplastic lesions in skin.
